David Kan

2.9k total citations
22 papers, 805 citations indexed

About

David Kan is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, David Kan has authored 22 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Genetics and 5 papers in Hematology. Recurrent topics in David Kan's work include HER2/EGFR in Cancer Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). David Kan is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). David Kan collaborates with scholars based in United States, Germany and Netherlands. David Kan's co-authors include Stephen Castaneda, Christine Flefleh, Amy Camuso, Ivan Inigo, Kelly McGlinchey, Shang‐Fan Yu, Jenny Boström, Franklin Peale, Wenyan Man and Germaine Fuh and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

David Kan

21 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Kan United States 13 368 322 310 148 117 22 805
Ivan Inigo United States 10 225 0.6× 363 1.1× 90 0.3× 146 1.0× 112 1.0× 21 693
Kelly McGlinchey United States 15 248 0.7× 603 1.9× 134 0.4× 169 1.1× 127 1.1× 30 1.1k
Lawrence Lai United States 11 308 0.8× 381 1.2× 557 1.8× 135 0.9× 81 0.7× 12 1.2k
R N Sridhara United States 5 343 0.9× 461 1.4× 272 0.9× 311 2.1× 80 0.7× 8 974
Sophie Derenne France 8 418 1.1× 362 1.1× 72 0.2× 338 2.3× 59 0.5× 11 780
Peter R. Blier United States 10 641 1.7× 136 0.4× 337 1.1× 112 0.8× 35 0.3× 14 1.1k
Gijs Verheijden Netherlands 11 313 0.9× 367 1.1× 385 1.2× 37 0.3× 32 0.3× 21 847
Lowell J. Underwood United States 12 420 1.1× 244 0.8× 122 0.4× 146 1.0× 273 2.3× 16 881
Stanley Frankel United States 13 514 1.4× 424 1.3× 97 0.3× 211 1.4× 240 2.1× 24 1.2k
Latha Sridharan United States 10 222 0.6× 367 1.1× 230 0.7× 77 0.5× 56 0.5× 11 656

Countries citing papers authored by David Kan

Since Specialization
Citations

This map shows the geographic impact of David Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kan more than expected).

Fields of papers citing papers by David Kan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kan. The network helps show where David Kan may publish in the future.

Co-authorship network of co-authors of David Kan

This figure shows the co-authorship network connecting the top 25 collaborators of David Kan. A scholar is included among the top collaborators of David Kan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kan. David Kan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lambdin, Barrot H., David Kan, & Alex H. Kral. (2022). Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs. Substance Abuse Treatment Prevention and Policy. 17(1). 51–51. 17 indexed citations
2.
Danovitch, Itai & David Kan. (2017). The Addiction Benefits Scorecard: A Framework to Promote Health Insurer Accountability and Support Consumer Engagement. Journal of Psychoactive Drugs. 49(2). 122–131. 1 indexed citations
3.
4.
Kan, David, et al.. (2015). Engaging veterans with substance abuse disorders into a research trial: success with study branding, networking, and presence. Translational Behavioral Medicine. 5(2). 167–176. 5 indexed citations
5.
Zhong, Yu, Paula Katavolos, Tien‐Trung Nguyen, et al.. (2015). Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1. Toxicologic Pathology. 44(2). 267–278. 69 indexed citations
6.
Boström, Jenny, Shang‐Fan Yu, David Kan, et al.. (2009). Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site. Science. 323(5921). 1610–1614. 263 indexed citations
7.
Chow, Patrick L, David Kan, Ricardo M. Attar, et al.. (2009). Effect of IGF-1R inhibitor BMS-754807 on tumor glucose metabolism and proliferation in Sal-IGF xenografts by FDG and FLT- PET imaging. Journal of Clinical Oncology. 27(15_suppl). e14501–e14501. 1 indexed citations
8.
Lee, Francis Y. F., Kelly L. Covello, Stephen Castaneda, et al.. (2008). Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models. Clinical Cancer Research. 14(24). 8123–8131. 37 indexed citations
9.
Camuso, Amy, Christine Flefleh, David Kan, et al.. (2006). Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. Journal of Clinical Oncology. 24(18_suppl). 12017–12017. 28 indexed citations
10.
Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2006). Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Research. 12(23). 7180–7186. 113 indexed citations
11.
Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations
12.
Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemotherapy and Pharmacology. 56(5). 455–464. 66 indexed citations
13.
Luo, Feng, Zheng Yang, Huijin Dong, et al.. (2005). Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model. Clinical Cancer Research. 11(15). 5558–5565. 22 indexed citations
14.
Lee, Francis Y., Mei-Li Wen, Rajeev S. Bhide, et al.. (2005). Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).. Blood. 106(11). 1994–1994. 14 indexed citations
15.
16.
Castaneda, Stephen, Ivan Inigo, David Kan, et al.. (2005). Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. Journal of Clinical Oncology. 23(16_suppl). 561–561. 26 indexed citations
17.
Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations
18.
Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2004). Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.. Blood. 104(11). 1987–1987. 1 indexed citations
19.
Wild, Robert A., Stephen Castaneda, Christine Flefleh, et al.. (2004). BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood. 104(11). 1988–1988. 9 indexed citations
20.
Kan, David. (1971). The impact of the cultural revolution on Chinese higher education. UMI Dissertation Information Service eBooks. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivan Inigo Breakdown of academic impact, for papers by Kelly McGlinchey Breakdown of academic impact, for papers by Lawrence Lai Breakdown of academic impact, for papers by R N Sridhara Breakdown of academic impact, for papers by Sophie Derenne Breakdown of academic impact, for papers by Peter R. Blier Breakdown of academic impact, for papers by Gijs Verheijden Breakdown of academic impact, for papers by Lowell J. Underwood Breakdown of academic impact, for papers by Stanley Frankel Breakdown of academic impact, for papers by Latha Sridharan
Rankless by CCL
2026